Neuroone Medical Technologies (NMTC) Price to Sales (2020 - 2026)

Neuroone Medical Technologies (NMTC) has reported Price to Sales for 7 consecutive years, with 13.41 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales fell 32.71% year-over-year to 13.41; the trailing twelve-month figure through Jun 2026 stood at 2.79 (down 45.2% YoY), and the FY2025 full-year result was 3.92, down 55.61% from the prior year.
• Price to Sales slipped to 13.41 in Q2 2026 per NMTC's latest filing, from 21.56 in the prior quarter.
• Across five years, Price to Sales topped out at 486.83 in Q1 2022 and bottomed at 7.78 in Q4 2024.
• Historically, Price to Sales has averaged 105.25 across 5 years, with a median of 24.96 in 2024.
• The sharpest annual moves came in 2023 and 2024: Price to Sales plunged 94.54% in 2023, then surged 415.15% in 2024.
• Over 5 years, Price to Sales stood at 170.07 in 2022, then plunged by 76.4% to 40.13 in 2023, then slumped by 80.62% to 7.78 in 2024, then jumped by 69.82% to 13.21 in 2025, then increased by 1.5% to 13.41 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 13.41, 21.56, and 13.21 for Q2 2026, Q1 2026, and Q4 2025 respectively.